Search the Newsreel

Assenagon Asset Management S.A. Buys 97,887 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Assenagon Asset Management S.A. significantly increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, purchasing an additional 97,887 shares to bring its total holdings to 102,862 shares valued at $8.855 million. This comes as Zimmer Biomet reported strong quarterly earnings, …

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of "Moderate Buy" by Analysts

Analysts have given BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) an average "Moderate Buy" rating, with a consensus 12-month price target of $88.00. The company recently reported strong quarterly results, with revenue up 20% year-over-year and raised its 2026 VOXZOGO revenue guidance to at least $1 billion. …

Orchestra BioMed (NASDAQ:OBIO) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Orchestra BioMed (NASDAQ:OBIO) reported a quarterly loss of $0.38 per share, missing analyst estimates by $0.03. Despite the earnings miss and negative financial metrics, the company's shares increased by 5.2% and insiders purchased a significant amount of stock. Analyst sentiment is mixed but generally …

Orchestra Biomed Holdings earnings beat by $0.01, revenue fell short of estimates

Orchestra Biomed Holdings (NASDAQ: OBIO) reported second-quarter EPS of $-0.380

Q3 EPS Estimate for Generate Biomedicines Lowered by Analyst

Biome Australia (ASX:BIO) Share Price in Focus for Health-Sector Investors

GENB Q2 2026 Earnings: Wider-than-Expected Loss in Pre-Revenue Quarter - Earnings Revision Downgrade

Advanced Biomed Inc (ADVB) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Advanced Biomed Inc (ADVB), covering future EPS, revenue, net profit, and EBIT growth estimates. It lists current stock performance metrics and offers a peer comparison with other healthcare companies like CVS Health Corp and HCA Healthcare Inc. …

Ping An Biomedical Ord Shs (PASW) Earnings Forecast: Future EPS & Revenue Growth Estimates

HARIOMPIPE Share Price Today - Hariom Pipe Industries Stock Analysis

Orchestra BioMed Holdings, Inc. Stock 12‑Month Price Target Raised to $12.33, Implies 177% Upside

The average 12-month price target for Orchestra BioMed Holdings, Inc. (OBIO) stock has increased to $12.33, up from $12.17, according to estimates from six analysts. This new target suggests a potential upside of approximately 177% from its closing price on August 10. The consensus …

Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day

Zimmer Biomet Holdings Inc. (ZBH) saw its stock advance by 1.27% to $97.78 on Monday, outperforming the broader market which experienced a dismal trading session. This rise broke a two-day losing streak for the company's shares. The S&P 500 Index and Dow Jones Industrial …

Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Orchestra BioMed announced its second-quarter 2026 financial results, highlighting progress in its two cardiovascular programs: AVIM Therapy and Virtue SAB. The company reported that its BACKBEAT trial for AVIM Therapy is on track to meet its target enrollment by Q3 2026, with primary data …

Orchestra BioMed reports $24.1M Q2 loss, secures $35M capital

Orchestra BioMed Holdings reported a net loss of $24.1 million in Q2 2026, widening from the previous year, despite an 89% drop in revenue to $88,000. The loss was primarily due to increased research and development expenses for pivotal clinical trials. However, the company …

BioMarin Pharmaceutical Inc. (BMRN) Stock Price, News, Quote & History

Orchestra BioMed Reports Q2 2026 Results and Updates Progress on BACKBEAT and Virtue Pivotal Trials

Orchestra BioMed reported its Q2 2026 financial results, including a net loss of $24.1 million, and provided updates on its pivotal clinical trials. The BACKBEAT Trial for uncontrolled hypertension is on track to enroll 284 patients by Q3 2026, with primary results expected in …

Orchestra BioMed (NASDAQ: OBIO) widens H1 2026 loss amid heavy R&D spend

Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates

Orchestra BioMed Holdings, Inc. (OBIO) reported a Q2 loss of $0.38 per share, missing the Zacks Consensus Estimate of a $0.35 loss, though it was an improvement from a $0.5 loss a year ago. The company also missed revenue estimates, posting $0.09 million against …

Biomarin Pharmaceutical stock hits 52-week high at 66.28 USD

BioMarin Pharmaceutical (BMRN) stock reached a new 52-week high of $66.28, reflecting a 16.44% increase over the past year. InvestingPro analysis suggests the stock is undervalued with strong fundamentals, including 11.2% revenue growth. The company also reported impressive Q2 2026 results, exceeding Wall Street …

BioMarin Pharmaceutical Aktie erreicht 52-Wochen-Hoch bei 66,28 USD

RBC cuts Oxford BioMedica target by a fifth but sticks with 'buy' call

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

SAN RAFAEL, Calif., Aug. 10, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced management will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston.BioMarin Pharmaceutical logo An audio webcast of the presentation …

BioMarin presentation to stream live from Boston on Aug. 12

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced it will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00 AM ET in Boston. A live audio webcast and a limited-time archived replay will be available on the company's investor …

Canaccord raises BioMarin stock price target on revenue growth

Canaccord has increased its price target for BioMarin Pharmaceutical Inc. (BMRN) to $114 from $111, maintaining a Buy rating, following strong second-quarter 2026 earnings. The company's revenue growth was significantly boosted by the acquisition of GALAFOLD and POMBILITI + OPFOLDA, leading to raised fiscal …

Zimmer Biomet (NYSE:ZBH) Price Target Raised to $100.00

Canaccord Genuity raised Zimmer Biomet's (NYSE:ZBH) price target from $83.00 to $100.00 while maintaining a "hold" rating, suggesting a 3.59% upside. The medical equipment provider recently reported strong quarterly earnings, beating EPS estimates by $0.06 and achieving a 4.8% year-over-year revenue increase. Analysts, on …

Price to earnings forward of Zimmer Biomet Holdings, Inc. – NYSE:ZBH

The article presents the "Price to earnings forward" value for Zimmer Biomet Holdings, Inc. (BX:ZIM) on TradingView. It appears to be a financial data point for the company, indicating its valuation based on future earnings expectations. The page also includes various navigation and information …

Orchestra BioMed (OBIO) Earnings Date and Reports 2026

HC Wainwright Expects Stronger Earnings for Biomea Fusion

Price to earnings forward of Zimmer Biomet Holdings, Inc. – BX:ZIM

The article presents the "Price to earnings forward" value for Zimmer Biomet Holdings, Inc. (BX:ZIM) on TradingView. It appears to be a financial data point for the company, indicating its valuation based on future earnings expectations. The page also includes various navigation and information …

Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Biomea Fusion, Inc. (NASDAQ:BMEA) has received a "Moderate Buy" consensus rating from six analysts, with an average 12-month price target of $8.20, significantly higher than its current share price of $1.26. Institutional investors hold a substantial 96.72% of the company, and several firms, including …

Zimmer Biomet Q2 Earnings Call Highlights

Key Points Interested in Zimmer Biomet Holdings, Inc.? Here are five stocks we like better. Zimmer Biomet reported solid Q2 growth: Net sales rose 4.8% to $2.177 billion, driven by hips, specialty businesses and technology. Adjusted EPS was $2.07, while U.S. organic sales increased …

Zimmer Biomet Holdings, Inc. (ZBH) Stock Price, News, Quote & History

This Yahoo Finance page provides a comprehensive overview of Zimmer Biomet Holdings, Inc. (ZBH) stock, including its current price, news, and historical data. It notes a recent downgrade by BTIG due to growth challenges and presents performance metrics against the S&P 500. The article …

BioMarin (BMRN) Is Up 6.3% After Raising 2026 Revenue Guidance And Highlighting Voxzogo Momentum

BioMarin Pharmaceutical Inc. (BMRN.MX) Analyst insights, Price targets and Recommendations

This article provides an overview of recent analyst ratings for BioMarin Pharmaceutical Inc. (BMRN.MX), including upgrades, downgrades, and maintained ratings from various financial institutions. It lists the latest price targets and recommendations from firms like Morgan Stanley, Oppenheimer, and Citigroup, along with the dates …

Generate Biomedicines (NASDAQ:GENB) Downgraded by Wall Street Zen to "Sell"

Wall Street Zen has downgraded Generate Biomedicines (NASDAQ:GENB) from "Hold" to "Sell," despite a broader analyst consensus of "Moderate Buy." This comes after the company reported a quarterly loss of $0.52 per share, missing estimates, and generated $6.31 million in revenue. Institutional activity includes …

Biomea Fusion, Inc. Stock 12‑Month Price Target Cut to $6.71, Implies 433% Upside

Seven analysts have revised Biomea Fusion, Inc.'s average 12-month price target down to $6.71 from $7, though this still represents a significant potential upside of approximately 433% from the August 5th closing price. The consensus rating for the stock remains a "Buy" among eight …